Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Abstract Text:

    mark e williamsMark E Williams,w kline boltonW Kline Bolton,raja g khalifahRaja G Khalifah,thorsten p degenhardtThorsten P Degenhardt,robert j schotzingerRobert J Schotzinger,janet b mcgillJanet B McGill,mark e williamsMark E Williams,w kline boltonW Kline Bolton,raja g khalifahRaja G Khalifah,thorsten p degenhardtThorsten P Degenhardt,robert j schotzingerRobert J Schotzinger,janet b mcgillJanet B McGill,

    BACKGROUND/AIMS: Treatments of diabetic nephropathy (DN) delay the onset of end-stage renal disease. We report the results of safety/tolerability studies in patients with overt nephropathy and type 1/type 2 diabetes treated with pyridoxamine, a broad inhibitor of advanced glycation. METHODS: The two 24-week studies were multicenter Phase 2 trials in patients under standard-of-care. In PYR-206, patients were randomized 1:1 and had baseline serum creatinine (bSCr) or=2.0 but or=1.3 mg/dl, type 2 diabetes), a treatment effect was observed on the rise in serum creatinine (p = 0.007). No differences in urinary albumin excretion were seen. Urinary TGF-beta1 also tended to decrease with pyridoxamine (p = 0.049) as did the CML and CEL AGEs. CONCLUSION: These data provide a foundation for further evaluation of this AGE inhibitor in DN.

    Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Publishing Authors By Initials

    me williamsME Williams,wk boltonWK Bolton,rg khalifahRG Khalifah,tp degenhardtTP Degenhardt,rj schotzingerRJ Schotzinger,jb mcgillJB McGill,me williamsME Williams,wk boltonWK Bolton,rg khalifahRG Khalifah,tp degenhardtTP Degenhardt,rj schotzingerRJ Schotzinger,jb mcgillJB McGill,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: American journal of nephrology

    VOLUME: 27

    Page Numbers: 605-14

    Journal Abbreviation: Am. J. Nephrol.

    ISSN: 1421-9670

    DAY: 6

    MONTH: 09

    YEAR: 2007

    Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8109361

    Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.

    AFFILIATION: Harvard Medical School, Joslin Diabetes Center, Boston, MA 02215, USA. mark.williams@joslin.harvard.edu

    Country: Switzerland

    Switzerland Research PublicationSwitzerland Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Am J Nephrol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News